EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Unveiling the biochemical signature of tumor-induced osteomalacia: implications for distinguishing it from primary osteoporosis

Yun Chai, Xin Wang, Sen Li, Zhiwang Wei, Qiusong Chen, Baoping Wang, Qing He, Ming Liu, Wenli Feng

Frontiers in Endocrinology · 24.07.2026 · 17

DOI: 10.3389/fendo.2026.1899331 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Endocrinology, online erschienen am 24.07.2026. Verfasst von Yun Chai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, China. Hauptthemen laut MEDLINE: Paraneoplastic Syndromes, Osteoporosis, Neoplasms, Connective Tissue, Biomarkers. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by FGF23-secreting tumors, resulting in renal phosphate wasting and hypophosphatemic osteomalacia. Low bone mineral density (BMD) in TIO frequently leads to misdiagnosis as the more prevalent primary osteoporosis (POP) and subsequent diagnostic delay. This study characterizes the distinct biochemical profile of TIO and proposes a stepwise diagnostic approach to differentiate it from POP for timely clinical identification and appropriate management.

Methods

We conducted a retrospective comparative analysis of 11 TIO patients and 12 POP patients managed at our institution over a 14-year period. Detailed clinical data were collected and compared between groups, including history, physical examination findings, laboratory results, imaging studies, and pathological outcomes.

Results

Comparative analysis revealed that, compared with POP patients, TIO patients had significantly lower serum calcium (2.19 ± 0.1 vs.2.3 ± 0.1 mmol/L, p < 0.05), serum phosphorus [0.46 (0.42, 0.6) vs. 1.15 (1.13, 1.23), p < 0.001], and the tubular maximum reabsorption of phosphate per glomerular filtration rate (TmP/GFR) (0.41 ± 0.2 vs.1.05 ± 0.15 mmol/L, p < 0.001). In contrast, ALP was significantly higher in the TIO cohort [317 (177.5, 344) vs. 79.5 (67.75, 86.75) U/L, p < 0.001]. No significant intergroup differences were observed in PTH levels or BMD.

Conclusions

We recommend serum phosphate, alkaline phosphatase, and TmP/GFR tests for symptomatic patients (e.g., bone pain, muscle weakness). Confirmed hypophosphatemia warrants FGF23 testing after excluding other causes of elevation. Subsequent bone X-ray and BMD guides the need for molecular imaging. The diagnostic gold standard comprises: (1) histopathological confirmation of the causative tumor, (2) rapid postoperative serum phosphate normalization, and (3) significant clinical improvement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Paraneoplastic SyndromesOsteoporosisNeoplasms, Connective TissueBiomarkersHumansFemaleRetrospective StudiesFibroblast Growth Factor-23MaleDiagnosis, DifferentialMiddle AgedBone DensityAgedFibroblast Growth FactorsPhosphorusOsteomalaciaAdultCalcium

Stichwörter der Autor:innen

diagnostic delaydifferential diagnosisfibroblast growth factor 23primary osteoporosistumor-induced osteomalacia

Substanzen

Fibroblast Growth Factor-23FGF23 protein, humanFibroblast Growth FactorsPhosphorusBiomarkersCalcium

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, China.
  • Department of General Internal Medicine, The Affiliated Hospital of Nankai University, Tianjin, China.
  • Department of General Surgery,Tianjin Medical University General Hospital, Tianjin, China.
  • Department of PET-CT Diagnostic,Tianjin Medical University General Hospital, Tianjin, China.

Zitieren

APA

Chai, Y., Wang, X., Li, S., Wei, Z., Chen, Q., Wang, B., He, Q., Liu, M., & Feng, W. (2026). Unveiling the biochemical signature of tumor-induced osteomalacia: implications for distinguishing it from primary osteoporosis. Frontiers in Endocrinology, 17. https://doi.org/10.3389/fendo.2026.1899331

Vancouver

Chai Y, Wang X, Li S, Wei Z, Chen Q, Wang B, et al. Unveiling the biochemical signature of tumor-induced osteomalacia: implications for distinguishing it from primary osteoporosis. Frontiers in Endocrinology. 2026;17. doi:10.3389/fendo.2026.1899331

BibTeX
@article{Chai2026,
  author = {Chai, Yun and Wang, Xin and Li, Sen and Wei, Zhiwang and Chen, Qiusong and Wang, Baoping and He, Qing and Liu, Ming and Feng, Wenli},
  title = {Unveiling the biochemical signature of tumor-induced osteomalacia: implications for distinguishing it from primary osteoporosis},
  journal = {Frontiers in Endocrinology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fendo.2026.1899331}
}
Kostenlos starten →